Automating clinical trial data validation when the world needed it most
Prior to the onset of COVID-19, Pfizer recognized an industry need for automated validation of statistical analysis outputs, and collaborated with Beaconcure to develop Verify. When the pandemic hit and the world needed it most, Pfizer was able to leverage Verify during COVID-19 vaccine studies.
Verify uses machine learning and natural language processing to validate statistical analysis outputs regardless of the format or structure. Pfizer uses Verify across study types and treatment areas to safely speed the availability of study validation results, delivery timelines, and ultimately, the time to submission.
The Results:
De-risked Submission
Enhanced submission quality by identifying and addressing issues early in the validation process.
First to Market
Introduced the vaccine to market faster, making various levels of immunity to COVID-19 accessible worldwide.
Early Release
Shortened submission timelines enabled earlier release and sales under the set IP timelines.
